Jump to content

Zhijian Chen

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Asdfghjohnkl (talk | contribs) at 00:09, 24 May 2020 (=> Chinese language template(s)). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

The native form of this personal name is Chen Zhijian. This article uses Western name order when mentioning individuals.
Zhijian "James" Chen
Born1966 (age 57–58)
Anxi County, Fujian, China
CitizenshipUnited States
EducationState University of New York at Buffalo
AwardsNAS Award in Molecular Biology (2012)
Lurie Prize in Biomedical Sciences (2018)
Breakthrough Prize in Life Sciences (2019)
Scientific career
Institutions

Zhijian "James" Chen (Chinese: 陈志坚; pinyin: Chén Zhìjiān; born 1966) is a Chinese-American biochemist and Professor in the Department of Molecular Biology at University of Texas Southwestern Medical Center. He is best known for his discovery of mechanisms by which nucleic acids trigger innate and autoimmune responses from the interior of a cell, work for which he received the 2019 Breakthrough Prize in Life Sciences.

Early life and education

Chen was born in Nandou Village (南斗) in Anxi County, Fujian, China. When he was young, his father was sent to Nanping for work, leaving his mother to raise him and his two brothers alone while she also worked as a primary school teacher. He graduated from Anxi No. 1 High School in 1981.[1] He attended Fujian Normal University and received an undergraduate degree in biology in 1985, before he won an overseas scholarship by getting first place in a biochemistry exam. Chen used the scholarship to attend the State University of New York at Buffalo, where he got his Ph.D. in biochemistry in 1991.[2][3] During his graduate education, Chen became interested in the biochemical pathway of the protein ubiquitin at a time when less than a dozen laboratories were researching the protein's function in the human body.[4] After graduating, Chen did a year of post-doctoral work with the Salk Institute for Biological Studies.[5]

Career

Following his post-doctoral work, Chen began working as a research scientist at Baxter Healthcare in Irvine, California. He then spent three years working as a senior scientist at biotech firm ProScript in Cambridge, Massachusetts, where he developed assays that helped to identify and improve the cancer treatment Velcade. His time at ProScript allowed Chen to work in molecular biology and drug development and it was while working there that Chen started researching ubiquitin.[3][5] Working with Tom Maniatis of Harvard University in 1996, Chen found that the enzyme kinase had to be "activated" by ubiquitin in order for the NF-κB signalling process to function properly. He decided pursuing his research into ubiquitin would be more suited for work in academia and left ProScript in 1997 to start a lab at the University of Texas Southwestern Medical Center in Dallas.[4] He currently holds the George L. MacGregor Distinguished Chair in Biomedical Science and is an Investigator of the Howard Hughes Medical Institute.[2]

Research

Chen's research initially focused on the role of ubiquitin in signaling pathways for the NF-κB protein complex, specifically as it pertains to immune response. At his lab in UT-Southwestern, Chen's group was able to show that ubiquitin marked proteins, marks that could be recognized by other proteins to create a "cascade" of signals.[4] His research received grant funding from the Burroughs Wellcome Fund in 2002[6] enabling research into how NF-κB initiated immune responses to RNA viruses such as influenza and hepatitis C. This new line of research led to the discovery of MAVS (Mitochondrial Anti-Viral Signaling protein) and the role of mitochondria in antiviral innate immune responses, and the more recent discoveries of the cytosolic DNA sensor, Cyclic GMP-AMP synthase (cGAS; cGAMP synthase), and a new second messenger, Cyclic guanosine monophosphate–adenosine monophosphate (cyclic GMP-AMP, cGAMP), which play key roles in immune defense as well as autoimmune diseases.[7]

Honors and awards

In 2018 Chen was awarded the Lurie Prize in Biomedical Sciences from the National Institutes of Health for his discovery of cGAS.[8]

Chen was awarded the 2019 Breakthrough Prize in Life Sciences for the discovery of the DNA-sensing enzyme cGAS and the pathways by which it activates innate immune responses. He shared the prize with C. Frank Bennett, Adrian R. Krainer, Angelika Amon, and Xiaowei Zhuang.[9] He has also received the Norman Hackerman Award in Chemical Research, The Edith and Peter O’Donnell Award in Science, and the National Academy of Sciences Award in Molecular Biology. He was elected to the National Academy of Sciences in 2014.[10]

References

  1. ^ "陈志坚当选美国科学院院士" (in Chinese). Fujian Association for Science and Technology. Retrieved 20 May 2014.
  2. ^ a b "James Chen, PhD - Faculty Profile". University of Texas Southwestern Medical Center. Retrieved 13 April 2012.
  3. ^ a b "HHMI Scientist Bio: Zhijian "James" Chen, Ph.D." Howard Hughes Medical Institute. Retrieved 16 April 2012.
  4. ^ a b c "Awardee Profile - James Chen". Burroughs Wellcome Fund. Retrieved 16 April 2012.
  5. ^ a b "The 2007 Edith and Peter O'Donnell Awards Recipients". The Academy of Medicine, Engineering and Science of Texas. Retrieved 16 April 2012.{{cite web}}: CS1 maint: url-status (link)
  6. ^ "PATH Grant Recipients". Burroughs Wellcome Fund. Retrieved 17 April 2012.
  7. ^ "NAS Award in Molecular Biology". National Academy of Sciences. Retrieved 13 April 2012.
  8. ^ "Lurie Prize in Biomedical Sciences". FNIH. Retrieved 13 December 2018.
  9. ^ "Breakthrough Prizes Recognize Aneuploidy Researcher, Biochemist". The Scientist Magazine. 18 October 2018. Retrieved 20 October 2018.
  10. ^ "Zhijian (James) Chen". National Academy of Sciences. 21 September 2018. Retrieved 20 October 2018.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Zhijian_Chen&oldid=958470198"